Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy
ABSTRACT Since the United States Food and Drug Administration approved the first immune checkpoint inhibitor ipilimumab for metastatic melanoma in 2011, ICIs have been approved for a range of cancers and significantly improving treatment outcomes. However, the objective response rate of ICI monother...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2025-09-01
|
| Schriftenreihe: | MedComm |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1002/mco2.70346 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|